Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Point of care is also known as with patient testing which allows physicians and medical staff to perfectly obtained real time, lab quality diagnostic results in several minute rather than taking hours to diagnose. Through the use of portable blood analysers, testing at the point of care downsize the diagnostic process and aids in ensuring patients to obtained the most effective and efficient care when and where it is needed. Point of care testing enables staff to make rapid triage and treatment decisions at the time of diagnosis of patient’s conditions or monitoring treatment response.
The Asia Pacific point of care diagnostic market is witnessing tremendous growth during forecast period of 2021 to 2027. The point of care diagnostic easier the testing process due to which clinicians can focus on what matters most for providing effective, quality patient care. The dynamic factors such as technological advancements and new product launches is propelling growth of Asia Pacific point of care diagnostic market. The rising funding for development of point of care products is also boosting growth of Asia Pacific point of care diagnostic market. However, pricing pressure owing to reimbursement cuts and budget constraints is hindering the growth of Asia Pacific point of care diagnostic market.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 3600 analysis of micro and macro-economic factors on the point of care diagnostic market. In addition, complete analysis of changes on point of care diagnostic expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on Asia Pacific economies, international trade, business investments, GDP and marketing strategies of key players present in the market. The outbreak of COVID-19 has boosted the growth of diagnostic kits for rapid detection of diseases. There is somewhat mismatch between the demand and supply as there is complete shutdown in many countries due to outbreak of COVID-19. The rapidly growing number of COVID-19 cases and the growing pressure on governments for improving patient management has boosted the demand for rapid antigen testing kits which can effectively use in point if care settings.
The Asia Pacific point of care diagnostic market is categorised into test type, mode of prescription, end user and country.
Product type such as glucose monitoring, cardiometabolic monitoring, infectious diseases monitoring, coagulation monitoring, pregnancy and fertility testing, faecal occult testing, haematology testing, tumour/cancer marker testing, urinalysis testing, drug abuse testing and cholesterol testing are comprised in the Asia Pacific point of care diagnostic market. In which urinalysis testing is also contributing to the growth of Asia Pacific point of care diagnostic market. The growing trend of home testing of biological samples is propelling growth of Asia Pacific point of care diagnostic market. The growing cases of urine infections is also boosting growth of Asia Pacific point of care diagnostic market.
Mode of prescriptions such as prescription based and over the counter product are comprised in the Asia Pacific point of care diagnostic market. In which prescription-based products is also contributing to the growth of Asia Pacific point of care diagnostic market. The rising awareness regarding use of point of care diagnostic products is boosting growth of Asia Pacific point of care diagnostic market. The rising prevalence of long term and chronic diseases is also propelling growth of Asia Pacific point of care diagnostic market.
End user such as hospitals/critical care centres, ambulatory care settings, research laboratories and home care are comprised in the Asia Pacific point of care diagnostic market. In which research laboratories are also contributing to the growth of Asia Pacific point of care diagnostic market. The rising research and development activities in point of care diagnostics is propelling growth of Asia Pacific point of care diagnostic market. The growing trend of home testing is also boosting growth of Asia Pacific point of care diagnostic market.
The Asia Pacific point of care diagnostic market is studied for key countries such as India, China, Japan, Australia and South Korea. In which China followed by India and Japan are anticipated to dominate the market in 2020. The rising prevalence of infectious diseases is propelling growth of Asia Pacific point of care diagnostic market. The growing healthcare expenditure is also boosting growth of Asia Pacific point of care diagnostic market.
The major key players operating in the market of point of care diagnostic market are Roche Diagnostics, Siemens Healthineers, Danaher Corporation, Becton Dickinson And Company, Abbott Laboratories, Quidel Diagnostics, Chembio Diagnostics, Ekf Diagnostics, Trinity Biotech and Fluxergy among others.
June 2019: Abott anouced the launch of Afinion HbA1c Dx Assay , a point of care test for diabetes.
June 2019: Quidel Corporation received US FDA approval to commercialize Quidel Triage TOX Drug Screen.
March 2019: Roche Diagnostics FDA approval for the VENTANA PD-L1 (SP142) Assay for identifying triple-negative breast cancer (TNBC) patients.
February 2019: Danaher acquired the Biopharma business of GE Life Sciences with an aim to established as a standalone operating company and strengthen the point of care diagnostics product portfolio.
The report analyses the point of care diagnostic market based on product type, mode of prescription, end user and country. Various types of products available in the point of care market are glucose monitoring, cardiometabolic monitoring, infectious diseases monitoring, coagulation monitoring, pregnancy and fertility testing, faecal occult testing, haematology testing, tumour/cancer marker testing, urinalysis testing, drug abuse testing and cholesterol testing. By mode of prescription, the market is segmented into the prescription based and over the counter products. Based on end users, the market is segmented into the hospital/critical care centres, ambulatory care settings, research laboratory and home care. The study also analyses the impact of COVID-19 on the point of care diagnostic market and it founds that the outbreak of COVID-19 has boosted the growth of diagnostic kits for rapid detection of diseases. There is somewhat mismatch between the demand and supply as there is complete shutdown in many countries due to outbreak of COVID-19. The rapidly growing number of COVID-19 cases and the growing pressure on governments for improving patient management has boosted the demand for rapid antigen testing kits which can effectively use in point if care settings. The study also analyses various major key players operating in the market.
Why to buy this report
